- Home
- LNT vs GMAB Comparison
LNT vs GMAB Comparison
Compare LNT & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LNT
- GMAB
- Stock Information
- Founded
- LNT 1917
- GMAB 1999
- Country
- LNT United States
- GMAB Denmark
- Employees
- LNT N/A
- GMAB N/A
- Industry
- LNT Power Generation
- GMAB Biotechnology: Pharmaceutical Preparations
- Sector
- LNT Utilities
- GMAB Health Care
- Exchange
- LNT Nasdaq
- GMAB Nasdaq
- Market Cap
- LNT 17.7B
- GMAB 17.4B
- IPO Year
- LNT N/A
- GMAB N/A
- Fundamental
- Price
- LNT $67.62
- GMAB $29.84
- Analyst Decision
- LNT Buy
- GMAB Strong Buy
- Analyst Count
- LNT 8
- GMAB 6
- Target Price
- LNT $69.38
- GMAB $40.40
- AVG Volume (30 Days)
- LNT 2.4M
- GMAB 2.6M
- Earning Date
- LNT 11-06-2025
- GMAB 11-06-2025
- Dividend Yield
- LNT 3.01%
- GMAB N/A
- EPS Growth
- LNT 23.58
- GMAB 132.41
- EPS
- LNT 3.18
- GMAB 25.10
- Revenue
- LNT $4,274,000,000.00
- GMAB $3,845,670,022.00
- Revenue This Year
- LNT $7.01
- GMAB $24.92
- Revenue Next Year
- LNT $4.91
- GMAB $15.97
- P/E Ratio
- LNT $21.17
- GMAB $1.16
- Revenue Growth
- LNT 7.77
- GMAB 29.57
- 52 Week Low
- LNT $56.30
- GMAB $17.24
- 52 Week High
- LNT $69.75
- GMAB $33.65
- Technical
- Relative Strength Index (RSI)
- LNT 52.97
- GMAB 52.96
- Support Level
- LNT $65.78
- GMAB $28.08
- Resistance Level
- LNT $68.24
- GMAB $29.35
- Average True Range (ATR)
- LNT 0.93
- GMAB 0.65
- MACD
- LNT -0.15
- GMAB -0.10
- Stochastic Oscillator
- LNT 47.03
- GMAB 83.57
About LNT Alliant Energy Corporation
Alliant Energy is the parent of two regulated utilities, Interstate Power and Light and Wisconsin Power and Light. Together, IPL and WPL serve nearly 1 million electric customers and 425,000 natural gas-only customers. Both subsidiaries engage in the generation and distribution of electricity and the distribution and transportation of natural gas. Alliant also owns a 16% interest in American Transmission Co.
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.